Researchers identify new drugs that could help prevent hearing loss

March 7, 2018, Rockefeller University Press
Compared with a normal mouse cochlea (top), cisplatin exposure reduces the number of outer hair cells (middle). But the loss of these cells is prevented by treatment with the CDK2 inhibitor kenpaullone (bottom). Credit: Teitz et al., 2018

Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study, which will be published March 7 in the Journal of Experimental Medicine, suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.

According to the World Health Organization, 360 million people worldwide, including 32 million children, suffer from caused by congenital defects or other factors. These factors include infectious disease, use of certain medicines, or exposure to excessive noise. Yet, there are currently no FDA-approved drugs to prevent or treat hearing loss.

A team of researchers led by Dr. Jian Zuo screened over 4,000 drugs for their ability to protect cochlear cells from the chemotherapy agent cisplatin. Cisplatin is used to treat a variety of cancers but causes irreversible hearing loss in up to 70% of patients.

Zuo and colleagues identified multiple compounds that protected cochlear cells from cisplatin, several of which are already approved to treat other conditions. Three of the ten most effective compounds were inhibitors of an enzyme called CDK2. One of these CDK2 inhibitors, kenpaullone, was more effective than four other compounds that are currently in clinical trials for treating hearing loss.

Injecting kenpaullone into the middle ear protected both mice and rats from cisplatin-induced hearing loss. Moreover, kenpaullone also protected the hearing of mice to noise as loud as 100 dB. "Given that 100-dB noise is in the range of noise insults commonly experienced by people in our society, kenpaullone could have significant clinical application in treating noise-induced hearing loss," says Zuo.

In the case of cisplatin-induced hearing loss, kenpaullone appears to protect hair cells by preventing CDK2 from stimulating the production of toxic from the cells' mitochondria.

"The robust protection conferred by one-time local delivery of kenpaullone suggests that CDK2 inhibitors may transform the clinical prevention and treatment of cisplatin- and noise-induced hearing loss in patients," Zuo says. "Modifications of the treatment regimens, additional optimization of the delivery methods via the use of hydrogels, and structural modifications of the compounds via medicinal chemistry could ensure even better results with CDK2 inhibitors in treating loss in humans."

Explore further: Preventing childhood deafness following chemotherapy treatment

More information: Tal Teitz et al, CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20172246

Related Stories

Preventing childhood deafness following chemotherapy treatment

September 12, 2017
Charity Action on Hearing Loss is supporting the biotechnology firm Otomagnetics, which today announces an important breakthrough towards preventing hearing loss caused by a widely used chemotherapy drug.

High prevalence of hearing loss seen after infant heart surgery

March 5, 2018
(HealthDay)—The prevalence of hearing loss in preschool children who had heart surgery in infancy may be above 20 percent, according to a study published in the January issue of The Journal of Pediatrics.

Guard against hearing loss from fireworks

July 4, 2017
(HealthDay)—Watching a fireworks display can be a treat for your eyes, but the noise can be a threat to your ears.

Study uncovers clues about why common cancer drug causes hearing loss

December 20, 2017
Scientists have found a new way to explain the hearing loss caused by cisplatin, a powerful drug used to treat many forms of cancer. Using a highly sensitive technique to measure and map cisplatin in mouse and human inner ...

Is your hearing at risk? Protect your ears

June 6, 2016
Hearing loss is a natural part of the aging process. But noise-induced hearing loss is on the rise.

White noise after loud noise prevents hearing deficits in mice

June 5, 2017
Mild hearing loss from exposure to less than one hour of loud noise leads to a reorganization of circuits in a key midbrain structure of the auditory system in mice, finds new research published in The Journal of Neuroscience. ...

Recommended for you

Human 'chimeric' cells restore crucial protein in Duchenne muscular dystrophy

March 16, 2018
Cells made by fusing a normal human muscle cell with a muscle cell from a person with Duchenne muscular dystrophy —a rare but fatal form of muscular dystrophy—were able to significantly improve muscle function when implanted ...

Team develops 3-D tissue model of a developing human heart

March 16, 2018
The heart is the first organ to develop in the womb and the first cause of concern for many parents.

Democratizing science: Researchers make neuroscience experiments easier to share, reproduce

March 16, 2018
Over the past few years, scientists have faced a problem: They often cannot reproduce the results of experiments done by themselves or their peers.

Genetic variant discovery to help asthma sufferers

March 16, 2018
Research from the University of Liverpool, published today in Lancet Respiratory Medicine, identifies a genetic variant that could improve the safety and effectiveness of corticosteroids, drugs that are used to treat a range ...

Researchers say use of artificial intelligence in medicine raises ethical questions

March 15, 2018
In a perspective piece, Stanford researchers discuss the ethical implications of using machine-learning tools in making health care decisions for patients.

Study identifies potential drug for treatment of debilitating inherited neurological disease

March 15, 2018
St. Jude Children's Research Hospital scientists have demonstrated in mouse studies that the neurological disease spinal bulbar muscular atrophy (SBMA) can be successfully treated with drugs. The finding paves the way for ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.